Can-Fite BioPharma Ltd. (NYSE:CANF) reported extended survival trends in a key late-stage cancer trial alongside a $4 million warrant exercise agreement to fund ongoing clinical operations.
• Can Fite Biopharma stock is at significant support. What is going on with CANF?
Phase 3 Liver Cancer Trial Progress
The clinical-stage biotechnology company observed longer-than-expected blinded overall survival in its ongoing pivotal Phase 3 trial evaluating Namodenoson for advanced hepatocellular carcinoma (HCC).
The study focuses on HCC patients with Child-Pugh B7 cirrhosis, utilizing overall survival as its primary efficacy endpoint.
Because the observed data reflect a pooled, blinded population across both treatment arms, the company cannot draw conclusions regarding drug efficacy or comparative differences yet.
However, due to the prolonged survival rates, management is assessing an earlier timeline for the trial’s planned interim analysis.
Warrant Exercise Secures $4 Million Gross Proceeds
In a concurrent financial update, the firm secured an immediate warrant exercise agreement for up to 1,591,738 American Depositary Shares (ADSs).
Originally issued in March 2026 with a $5 exercise price, the company reduced the exercise price to $2.50 per ADS to encourage immediate cash execution.
To incentivize the transaction, the business will issue new unregistered warrants allowing holders to purchase up to 3,183,476 additional ADSs at $2.50 per share.
The initial exercise generates roughly $4 million in gross proceeds prior to deducting placement agent fees.
Management plans to allocate the net capital toward research and development, clinical trials, working capital and general corporate activities.
CANF Stock Price Activity: Can Fite Biopharma shares were down 22.49% at $2.55 at the time of publication Wednesday, according to Benzinga Pro data.
Photo Courtesy: Shutterstock.com
Login to comment